POVAL KOGYO Co., Ltd. (TYO:4247)
1,250.00
+15.00 (1.21%)
Aug 4, 2025, 2:14 PM JST
Verve Therapeutics Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 1,025 | 834 | 1,217 | 1,235 | 1,151 | Upgrade |
Cash & Short-Term Investments | 1,025 | 834 | 1,217 | 1,235 | 1,151 | Upgrade |
Cash Growth | 22.90% | -31.47% | -1.46% | 7.30% | -15.55% | Upgrade |
Receivables | 838 | 839 | 876 | 869 | 710 | Upgrade |
Inventory | 1,097 | 1,130 | 1,108 | 964 | 950 | Upgrade |
Other Current Assets | 53 | 77 | 39 | 39 | 57 | Upgrade |
Total Current Assets | 3,013 | 2,880 | 3,240 | 3,107 | 2,868 | Upgrade |
Property, Plant & Equipment | 3,249 | 3,114 | 2,544 | 2,500 | 2,429 | Upgrade |
Long-Term Investments | 695 | 734 | 715 | 762 | 820 | Upgrade |
Goodwill | - | - | - | 5 | 19 | Upgrade |
Other Intangible Assets | 22 | 6 | 7 | 5 | 5 | Upgrade |
Long-Term Deferred Tax Assets | 151 | 122 | 125 | 116 | 86 | Upgrade |
Other Long-Term Assets | 2 | 1 | 2 | 2 | - | Upgrade |
Total Assets | 7,152 | 6,877 | 6,653 | 6,517 | 6,227 | Upgrade |
Accounts Payable | 295 | 327 | 291 | 339 | 342 | Upgrade |
Accrued Expenses | 73 | 70 | 73 | 73 | 74 | Upgrade |
Short-Term Debt | 220 | 20 | 20 | 20 | 20 | Upgrade |
Current Income Taxes Payable | 53 | 50 | 78 | 77 | 64 | Upgrade |
Other Current Liabilities | 305 | 207 | 198 | 247 | 175 | Upgrade |
Total Current Liabilities | 946 | 674 | 660 | 756 | 675 | Upgrade |
Other Long-Term Liabilities | 29 | 38 | 34 | 10 | 10 | Upgrade |
Total Liabilities | 1,435 | 1,152 | 1,111 | 1,161 | 1,070 | Upgrade |
Common Stock | 179 | 179 | 179 | 179 | 179 | Upgrade |
Additional Paid-In Capital | 275 | 275 | 275 | 275 | 275 | Upgrade |
Retained Earnings | 4,879 | 4,897 | 4,808 | 4,649 | 4,451 | Upgrade |
Comprehensive Income & Other | 373 | 354 | 261 | 235 | 235 | Upgrade |
Total Common Equity | 5,706 | 5,705 | 5,523 | 5,338 | 5,140 | Upgrade |
Minority Interest | 11 | 20 | 19 | 18 | 17 | Upgrade |
Shareholders' Equity | 5,717 | 5,725 | 5,542 | 5,356 | 5,157 | Upgrade |
Total Liabilities & Equity | 7,152 | 6,877 | 6,653 | 6,517 | 6,227 | Upgrade |
Total Debt | 220 | 20 | 20 | 20 | 20 | Upgrade |
Net Cash (Debt) | 805 | 814 | 1,197 | 1,215 | 1,131 | Upgrade |
Net Cash Growth | -1.11% | -32.00% | -1.48% | 7.43% | -15.79% | Upgrade |
Net Cash Per Share | 305.55 | 308.97 | 454.34 | 461.18 | 429.28 | Upgrade |
Filing Date Shares Outstanding | 2.63 | 2.63 | 2.63 | 2.63 | 2.63 | Upgrade |
Total Common Shares Outstanding | 2.63 | 2.63 | 2.63 | 2.63 | 2.63 | Upgrade |
Working Capital | 2,067 | 2,206 | 2,580 | 2,351 | 2,193 | Upgrade |
Book Value Per Share | 2165.82 | 2165.44 | 2096.35 | 2026.13 | 1950.98 | Upgrade |
Tangible Book Value | 5,684 | 5,699 | 5,516 | 5,328 | 5,116 | Upgrade |
Tangible Book Value Per Share | 2157.46 | 2163.16 | 2093.70 | 2022.34 | 1941.87 | Upgrade |
Order Backlog | 441.08 | 385.92 | 376.43 | 464.17 | 396.66 | Upgrade |
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.